New hope for aggressive lymphoma: targeted combo trial launches
NCT ID NCT07511114
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug combination (C Pola R-CHP+X) works better than the standard treatment (CR-CHOP) for people with a fast-growing type of lymphoma called double-expressor diffuse large B-cell lymphoma. About 156 adults aged 18-75 who have not been treated before will take part. The goal is to see if the new combo leads to more complete remissions and longer survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE-EXPRESSOR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••